ReviewCurrent hypertension reports2016
Loop Diuretics in the Treatment of Hypertension.
Review in Current hypertension reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019).Hypertension research : official journal of the Japanese Society of Hypertension · 2019Guideline
- Self-Nanoemulsifying Drug Delivery Systems for Cardiovascular Therapeutics: Formulation Strategies, Pharmacokinetic Enhancement and Precision-Oriented Translation.Journal of cardiovascular translational research · 2026Review
- Hyponatremia in geriatric patients.Zeitschrift fur Gerontologie und Geriatrie · 2025Article
- Structural bases for NaNature communications · 2024Article
- Considering Adverse Effects of Common Antihypertensive Medications in the ED.Current hypertension reports · 2024Review
- In Vivo Diuretic Activity and Anti-Hypertensive Potential ofFoods (Basel, Switzerland) · 2024Article
- Quality of medicines for Cardio-Vascular Diseases (CVDs) in the Ethiopian border with Kenya: The case of enalapril maleate and furosemide tablet quality in Borena and Gedeo zones.PLOS global public health · 2024Article
- Repurposing antihypertensive drugs for pain disorders: a drug-target mendelian randomization study.Frontiers in pharmacology · 2024Article
- Hyponatremia in patients with arterial hypertension: pathophysiology and management.Archives of medical science : AMS · 2023Article
- Structure of the human cation-chloride cotransport KCC1 in an outward-open state.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Structural basis for inhibition of the Cation-chloride cotransporter NKCC1 by the diuretic drug bumetanide.Nature communications · 2022Article
- The Road to Better Management in Resistant Hypertension-Diagnostic and Therapeutic Insights.Pharmaceutics · 2021Review
- Recent advances in the diagnosis and management of amyloid cardiomyopathy.Faculty reviews · 2021Review
- Review
- Addressing Comorbidities in Heart Failure: Hypertension, Atrial Fibrillation, and Diabetes.Heart failure clinics · 2020Review
- Consensus paper on the evaluation and treatment of resistant hypertension by the Turkish Society of Cardiology.Anatolian journal of cardiology · 2020Article
- Structure of the human cation-chloride cotransporter NKCC1 determined by single-particle electron cryo-microscopy.Nature communications · 2020Article
- Clinical Usefulness of Furosemide to Prevent Volume Overload Among Children and Young Adults with Transfusion-Dependent Thalassemia: A Randomized, Open-Label, Crossover Study.Journal of blood medicine · 2020Article
- Resistant Hypertension: Where are We Now and Where Do We Go from Here?Integrated blood pressure control · 2020Review
- Visual Snow: a Potential Cortical Hyperexcitability Syndrome.Current treatment options in neurology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Loop diuretics are not recommended in current hypertension guidelines largely due to the lack of outcome data. Nevertheless, they have been shown to lower blood pressure and to offer potential advantages over thiazide-type diuretics. Torsemide offers advantages of longer duration of action and once daily dosing (vs. furosemide and bumetanide) and more reliable bioavailability (vs. furosemide). Studies show that the previously employed high doses of thiazide-type diuretics lower BP more than furosemide. Loop diuretics appear to have a preferable side effect profile (less hyponatremia, hypokalemia, and possibly less glucose intolerance). Studies comparing efficacy and side effect profiles of loop diuretics with the lower, currently widely prescribed, thiazide doses are needed. Research is needed to fill gaps in knowledge and common misconceptions about loop diuretic use in hypertension and to determine their rightful place in the antihypertensive arsenal.
Indexed as
Identifiers
26951244What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.